| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Anna-Marie Fairhurst | Q37370363 |
| P2093 | author name string | Teja Celhar | |
| P2860 | cites work | TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease | Q22254041 |
| Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein | Q24291950 | ||
| Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans | Q24562483 | ||
| BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator | Q28139180 | ||
| Of mice and not men: differences between mouse and human immunology | Q28246229 | ||
| Accelerated appearance of neoplasms in female nzb/nzw mice treated with high-dose cyclophosphamide | Q28325221 | ||
| Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice | Q28591902 | ||
| Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees | Q28776419 | ||
| Activators and target genes of Rel/NF-kappaB transcription factors | Q29547882 | ||
| Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis | Q30080034 | ||
| NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci | Q30307755 | ||
| Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis | Q30312212 | ||
| Cgnz1 allele confers kidney resistance to damage preventing progression of immune complex-mediated acute lupus glomerulonephritis | Q30413753 | ||
| Development of murine lupus involves the combined genetic contribution of the SLAM and FcgammaR intervals within the Nba2 autoimmune susceptibility locus | Q30433488 | ||
| Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. | Q33415332 | ||
| Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. | Q33659691 | ||
| Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients | Q33662822 | ||
| Elevated double negative T cells in pediatric autoimmunity | Q33717456 | ||
| Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus | Q41873579 | ||
| The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice | Q41915761 | ||
| Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus | Q41921379 | ||
| Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice | Q43658790 | ||
| Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice | Q44114226 | ||
| A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice | Q44175614 | ||
| Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice. | Q44397965 | ||
| Differential effect of the autoimmune Yaa and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice | Q44497250 | ||
| Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease | Q44663778 | ||
| Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model | Q44766216 | ||
| Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide | Q44996901 | ||
| Modulation of nuclear factor-kappaB activity can influence the susceptibility to systemic lupus erythematosus | Q45025185 | ||
| Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus | Q45180946 | ||
| Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. | Q45946848 | ||
| A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). | Q46055629 | ||
| Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide | Q46448087 | ||
| BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. | Q46726060 | ||
| Microarray analysis of glomerular gene expression in murine lupus nephritis | Q46813534 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| Attenuation of murine lupus nephritis by mycophenolate mofetil. | Q47714353 | ||
| Systemic lupus erythematosus. | Q50848358 | ||
| Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity. | Q50949568 | ||
| The problems and pitfalls in systemic lupus erythematosus drug discovery | Q89270942 | ||
| New Zealand mixed mice: a genetic systemic lupus erythematosus model for assessing environmental effects | Q33741182 | ||
| PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus | Q33849511 | ||
| Type I interferon in the pathogenesis of lupus | Q33852174 | ||
| Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus | Q33974263 | ||
| Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus | Q34063315 | ||
| Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model | Q34230589 | ||
| TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus | Q34241004 | ||
| Similarities and differences between selective and nonselective BAFF blockade in murine SLE | Q34350295 | ||
| Yaa autoimmune phenotypes are conferred by overexpression of TLR7. | Q34356566 | ||
| Role of early repeated renal biopsies in lupus nephritis | Q34424633 | ||
| Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. | Q34650870 | ||
| CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance | Q34654251 | ||
| A Tlr7 translocation accelerates systemic autoimmunity in murine lupus | Q34773105 | ||
| Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice | Q34775978 | ||
| B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice | Q34781487 | ||
| Murine lupus susceptibility locus Sle2 activates DNA-reactive B cells through two sub-loci with distinct phenotypes | Q34842443 | ||
| Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys | Q34892862 | ||
| Cyclophosphamide and cancer: golden anniversary | Q35005506 | ||
| Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus | Q35035048 | ||
| IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice | Q35118781 | ||
| CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus | Q35128133 | ||
| The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression | Q35200339 | ||
| B cell-intrinsic CD84 and Ly108 maintain germinal center B cell tolerance. | Q35472364 | ||
| Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors | Q35544326 | ||
| Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials | Q35544692 | ||
| The discovery and development of belimumab: the anti-BLyS-lupus connection | Q35691272 | ||
| Methylprednisolone attenuates lipopolysaccharide-induced Fractalkine expression in kidney of Lupus-prone MRL/lpr mice through the NF-kappaB pathway | Q35756700 | ||
| Sex chromosome aneuploidies among men with systemic lupus erythematosus | Q35842781 | ||
| Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication | Q38313174 | ||
| Animal models of lupus and lupus nephritis | Q38380486 | ||
| The evolution of drug discovery in systemic lupus erythematosus | Q38540167 | ||
| An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus | Q38546315 | ||
| Translating nucleic acid-sensing pathways into therapies | Q38570333 | ||
| Associations between the FAS -670 A/G, -1377 G/A, and FASL -844 T/C polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis | Q38799630 | ||
| Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis | Q38884826 | ||
| Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis | Q38922720 | ||
| Understanding remission in real-world lupus patients across five European countries. | Q40243855 | ||
| Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid | Q40265943 | ||
| Regulation of B cell tolerance by the lupus susceptibility gene Ly108. | Q40267209 | ||
| Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates | Q40779546 | ||
| Association between toll-like receptor polymorphisms and systemic lupus erythematosus: a meta-analysis update | Q40980734 | ||
| Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous | Q41006064 | ||
| Treatment Algorithms in Systemic Lupus Erythematosus | Q41207949 | ||
| Studies of consomic mice bearing the Y chromosome of the BXSB mouse | Q41382497 | ||
| Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families | Q41612386 | ||
| Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset | Q36054583 | ||
| Microbiota at the crossroads of autoimmunity | Q36071864 | ||
| Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus | Q36102468 | ||
| Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus | Q36126483 | ||
| Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains | Q36342054 | ||
| Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations | Q36375661 | ||
| Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice | Q36399066 | ||
| Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. | Q36475603 | ||
| Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice | Q36490737 | ||
| B cell TLR7 expression drives anti-RNA autoantibody production and exacerbates disease in systemic lupus erythematosus-prone mice | Q36532226 | ||
| Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. | Q36673286 | ||
| Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients | Q37052138 | ||
| IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model | Q37125180 | ||
| Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans | Q37143371 | ||
| IFNα Inducible Models of Murine SLE. | Q37210594 | ||
| Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation | Q37252315 | ||
| Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. | Q37311032 | ||
| Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. | Q37351980 | ||
| Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus | Q37363440 | ||
| A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease | Q37371654 | ||
| Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease | Q37396863 | ||
| Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study | Q37398870 | ||
| Murine models of cutaneous involvement in lupus erythematosus | Q37400347 | ||
| Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus | Q37633408 | ||
| Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche | Q37662690 | ||
| The role of antimalarial agents in the treatment of SLE and lupus nephritis | Q37947108 | ||
| TLR7 and TLR9 in SLE: when sensing self goes wrong | Q37995556 | ||
| New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. | Q38026787 | ||
| The BAFF/APRIL system in SLE pathogenesis. | Q38194895 | ||
| The efficacy of novel B cell biologics as the future of SLE treatment: a review | Q38242432 | ||
| Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model | Q38245655 | ||
| Genomic view of IFN-alpha response in pre-autoimmune NZB/W and MRL/lpr mice | Q38298730 | ||
| Association of a single nucleotide polymorphism in the SH2D1A intronic region with systemic lupus erythematosus. | Q51253375 | ||
| Abatacept for systemic lupus erythematosus: the outlook. | Q51560845 | ||
| Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. | Q51561753 | ||
| Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. | Q51736584 | ||
| Intervention of CD4+ cell subset shifts and autoimmunity in the BXSB mouse by murine CTLA4Ig. | Q52049439 | ||
| Origin of CD4-CD8-B220+ T cells in MRL-lpr/lpr mice. Clues from a T cell receptor beta transgenic mouse | Q52225633 | ||
| Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. | Q52939927 | ||
| Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus. | Q54231271 | ||
| Selective suppression of autoantibody responses in NZB/NZW MICE treated with long-term cyclophosphamide | Q54626267 | ||
| Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways | Q56908183 | ||
| Dissection of BXSB Lupus Phenotype Using Mice Congenic for Chromosome 1 Demonstrates That Separate Intervals Direct Different Aspects of Disease | Q57089490 | ||
| Identification of intervals on chromosomes 1, 3, and 13 linked to the development of lupus in BXSB mice | Q57089565 | ||
| Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice | Q57089590 | ||
| Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans | Q57329877 | ||
| Mycophenolate Mofetil Ameliorates Perivascular T Lymphocyte Inflammation and Reduces the Double-Negative T Cell Population in SLE-Prone MRLlpr/lpr Mice | Q60194309 | ||
| CYCLOPHOSPHAMIDE TREATMENT OF RENAL DISEASE IN (NZB × NZW) F1 HYBRID MICE | Q60300214 | ||
| Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy | Q66912449 | ||
| Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW MICE | Q66930613 | ||
| Glucocorticoid ameliorates altered gene expression of extracellular matrix components in kidneys of New Zealand black/white F1 mice | Q67509086 | ||
| Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only | Q67925070 | ||
| The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW x C57BL/6)F1 male mice, but not in C57BL/6 male mice | Q68094972 | ||
| Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs | Q68859513 | ||
| Monocyte function in systemic lupus erythematosus | Q69208349 | ||
| Immunosuppression by cyclophosphamide in NZB X NZW mice with lupus nephritis | Q70093102 | ||
| Murine lupus nephritis. Effects of glucocorticoid on circulating and tissue-bound immunoreactants | Q70994276 | ||
| Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis | Q71002422 | ||
| Cyclophosphamide-induced changes in the MRL-lpr/lpr mouse: effects upon cellular composition, immune function, and disease | Q71002429 | ||
| Murine lupus nephritis. Effects of glucocorticoid on glomerular permeability | Q71304887 | ||
| Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus | Q72993248 | ||
| Functional dissection of systemic lupus erythematosus using congenic mouse strains | Q73433330 | ||
| Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII | Q73514724 | ||
| Inflamed kidneys of NZB / W mice are a major site for the homeostasis of plasma cells | Q74460576 | ||
| Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus | Q74540694 | ||
| Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus | Q77702000 | ||
| Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death | Q77823495 | ||
| Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice | Q77850765 | ||
| Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms | Q79946741 | ||
| Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus | Q80219157 | ||
| Type I IFN protects against murine lupus | Q80363125 | ||
| Depletion of B cells in murine lupus: efficacy and resistance | Q80819752 | ||
| Sle3 and Sle5 can independently couple with Sle1 to mediate severe lupus nephritis | Q80866792 | ||
| Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus | Q81595401 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | suppl_1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| Mus | Q39275 | ||
| animal disease model | Q64732998 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | i88-i99 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Modelling clinical systemic lupus erythematosus: similarities, differences and success stories | |
| P478 | volume | 56 |
| Q55357541 | Androgen-Induced Immunosuppression. |
| Q64114060 | Cardiac phenotype in mouse models of systemic autoimmunity |
| Q57296306 | Developmental origin and sex-specific risk for infections and immune diseases later in life |
| Q98735477 | Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus |
| Q92734901 | Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research |
| Q90354518 | Infection with Opportunistic Bacteria Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice |
| Q55489605 | Role of Interleukin-38 in Chronic Inflammatory Diseases: A Comprehensive Review. |
Search more.